Liu Peter Y, Swerdloff Ronald S, Anawalt Bradley D, Anderson Richard A, Bremner William J, Elliesen Joerg, Gu Yi-Qun, Kersemaekers Wendy M, McLachlan Robert I, Meriggiola M Cristina, Nieschlag Eberhard, Sitruk-Ware Regine, Vogelsong Kirsten, Wang Xing-Hai, Wu Frederick C W, Zitzmann Michael, Handelsman David J, Wang Christina
Department of Andrology, ANZAC Research Institute, University of Sydney and Concord Hospital, Concord, New South Wales 2139, Australia.
J Clin Endocrinol Metab. 2008 May;93(5):1774-83. doi: 10.1210/jc.2007-2768. Epub 2008 Feb 26.
Male hormonal contraceptive methods require effective suppression of sperm output.
The objective of the study was to define the covariables that influence the rate and extent of suppression of spermatogenesis to a level shown in previous World Health Organization-sponsored studies to be sufficient for contraceptive purposes (< or =1 million/ml).
This was an integrated analysis of all published male hormonal contraceptive studies of at least 3 months' treatment duration.
Deidentified individual subject data were provided by investigators of 30 studies published between 1990 and 2006.
A total of 1756 healthy men (by physical, blood, and semen exam) aged 18-51 yr of predominantly Caucasian (two thirds) or Asian (one third) descent were studied. This represents about 85% of all the published data.
INTERVENTION(S): Men were treated with different preparations of testosterone, with or without various progestins.
Semen analysis was the main measure.
Progestin coadministration increased both the rate and extent of suppression. Caucasian men suppressed sperm output faster initially but ultimately to a less complete extent than did non-Caucasians. Younger age and lower initial blood testosterone or sperm concentration were also associated with faster suppression, but the independent effect sizes for age and baseline testicular function were relatively small.
Male hormonal contraceptives can be practically applied to a wide range of men but require coadministration of an androgen with a second agent (i.e. progestin) for earlier and more complete suppression of sperm output. Whereas considerable progress has been made toward defining clinically effective combinations, further optimization of androgen-progestin treatment regimens is still required.
男性激素避孕方法需要有效抑制精子产生。
本研究的目的是确定影响精子发生抑制速率和程度的协变量,使其达到世界卫生组织先前资助研究中所示的足以达到避孕目的的水平(≤100万/ml)。
这是一项对所有已发表的治疗持续时间至少为3个月的男性激素避孕研究的综合分析。
30项在1990年至2006年间发表的研究的研究者提供了经过身份识别处理的个体受试者数据。
共研究了1756名年龄在18 - 51岁之间、主要为白种人(三分之二)或亚洲人(三分之一)血统的健康男性(通过体格、血液和精液检查)。这代表了所有已发表数据的约85%。
男性接受不同制剂的睾酮治疗,有或没有各种孕激素。
精液分析是主要指标。
联合使用孕激素可提高抑制速率和程度。白种男性最初抑制精子输出的速度更快,但最终的抑制程度不如非白种人。年龄较小以及初始血液睾酮或精子浓度较低也与更快的抑制相关,但年龄和基线睾丸功能的独立效应大小相对较小。
男性激素避孕药可实际应用于广泛的男性群体,但需要将雄激素与第二种药物(即孕激素)联合使用,以更早、更完全地抑制精子输出。虽然在确定临床有效组合方面已取得相当大的进展,但仍需要进一步优化雄激素 - 孕激素治疗方案。